Details for New Drug Application (NDA): 208399
✉ Email this page to a colleague
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this compound. Additional details are available on the rolapitant hydrochloride profile page.
Summary for 208399
Tradename: | VARUBI |
Applicant: | Tersera |
Ingredient: | rolapitant hydrochloride |
Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208399
Generic Entry Date for 208399*:
Constraining patent/regulatory exclusivity:
Dosage:
EMULSION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | EMULSION;INTRAVENOUS | Strength | EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) | ||||
Approval Date: | Oct 25, 2017 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 19, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 4, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 4, 2027 | Product Flag? | Y | Substance Flag? | Y | Delist Request? |
Expired US Patents for NDA 208399
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Tersera | VARUBI | rolapitant hydrochloride | EMULSION;INTRAVENOUS | 208399-001 | Oct 25, 2017 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription